Tenax Therapeutics, Inc. (TENX) Stock Price & Analysis
Tenax Therapeutics, Inc. (TENX) fell 0.75% to USD 14.53 as of July 25, 2026 at 04:39 UTC, according to Nexqual real-time market data.
TENX last closed at USD 14.64; the session ranged USD 14.22–14.84 on volume of 1,160,113 shares. Market capitalization is $385.41M, with a 52-week range of USD 5.78–19.4 (NCM). Source: Nexqual, July 25, 2026 at 04:39 UTC.
Key Statistics (as of July 25, 2026 at 04:39 UTC)
| Price | USD 14.53 |
|---|---|
| Change | ▼ 0.75% (down) |
| Previous Close | USD 14.64 |
| Open | USD 14.6 |
| Day Range | USD 14.22 – 14.84 |
| 52-Week Range | USD 5.78 – 19.4 |
| Volume | 1,160,113 shares |
| Market Cap | $385.41M |
| Exchange | NCM |
Technical Analysis (TENX)
Nexqual's technical model rates TENX "BUY" based on 4 bullish and 2 bearish signals across 125 daily candles, as of July 25, 2026 at 04:39 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 50.72 (neutral) |
| vs SMA50 | Above (USD 13.23) |
| MACD | 0.49 (positive) |
Analyst Ratings (TENX)
Wall Street analysts rate TENX "Strong Buy" based on 9 analysts, with a mean price target of USD 35.22 (range USD 26–50), per Nexqual as of July 25, 2026 at 04:39 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 9 |
| Mean Target | USD 35.22 |
| High Target | USD 50 |
| Low Target | USD 26 |
| Buy / Hold / Sell | 9 / 0 / 0 |
Earnings (TENX)
| EPS Estimate | USD -0.36 |
|---|---|
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.35 vs est -0.4 ▲ beat |
| 2025-12-31 | USD -0.38 vs est -0.42 ▲ beat |
| 2025-09-30 | USD -0.4 vs est -1.12 ▲ beat |
| 2025-06-30 | USD -0.27 vs est -0.45 ▲ beat |
Source: Nexqual, July 25, 2026 at 04:39 UTC.
Financials & Fundamentals (TENX)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -51.71% |
| Current Ratio | 14.52 |
| Total Cash | $118.75M |
| Total Debt | $0 |
| Free Cash Flow | $-18.75M |
Source: Nexqual, July 25, 2026 at 04:39 UTC.
Financial Health Score (TENX)
Nexqual rates Tenax Therapeutics, Inc.'s overall financial health "Weak" across five dimensions, as of July 25, 2026 at 04:39 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Mixed — $119M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$38M |
| Efficiency | Critical — ROE -52%, ROA -32.7% |
Ownership (TENX)
| Insider Ownership | +0.15% |
|---|---|
| Institutional Ownership | +75.82% |
| Shares Outstanding | 26.53M |
| Float | 26.47M |
| Short % of Float | +7.81% |
Source: Nexqual, July 25, 2026 at 04:39 UTC.
Leadership (TENX)
Tenax Therapeutics, Inc. is led by Christopher T. Giordano (age 50), CEO, President & Director, per Nexqual as of July 25, 2026 at 04:39 UTC.
| CEO, President & Director | Christopher T. Giordano (age 50) |
|---|---|
| Chief Medical Officer & Director | Stuart Rich (age 75) |
| Chief Financial Officer | Thomas R. Staab II (age 57) |
| Executive Vice President of Regulatory Affairs | Douglas Hay |
| Executive Vice President of Clinical Development & Strategy | So-Young Kim |
Major Backers & Investors (TENX)
Notable institutional backers of Tenax Therapeutics, Inc. include Price (T.Rowe) Associates Inc, T. Rowe Price, Janus Henderson Group PLC, according to Nexqual as of July 25, 2026 at 04:39 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Price (T.Rowe) Associates Inc | 11.13% |
| T. Rowe Price | 9.92% |
| Janus Henderson Group PLC | 6.84% |
| Venrock Adviser, LLC | 6.32% |
| Perceptive Advisors Llc | 5.46% |
| Ikarian Capital, LLC | 3.84% |
| Stonepine Capital Management, LLC | 3.68% |
| Logos Global Management LP | 2.36% |
Source: Nexqual, July 25, 2026 at 04:39 UTC.
From Tenax Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-10)
Key Strengths & Strategy (as disclosed to the SEC)
- Tenax Therapeutics, Inc., a development-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States.
- It develops TNX-101, TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension in heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| BPTH | Bio-Path Holdings, Inc. | USD 0.04 | ▲ 0% |
| VTVT | vTv Therapeutics Inc. | USD 30.73 | ▼ 2.97% |
| PULM | Pulmatrix, Inc. | USD 1.65 | ▼ 2.37% |
| ADIL | Adial Pharmaceuticals, Inc | USD 2.78 | ▲ 2.96% |
| CFOR | OpGen, Inc. | USD 18 | ▼ 10% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 04:39 UTC. This page is informational and not investment advice.